93 results about "Brains tissue" patented technology

The invention provides a rigidity-flexibility variable multifunctional optical genetic implantable probe and a preparation method thereof. The probe comprises a thin film electrode layer and a rigidity-flexibility variable shape memory layer arranged at the bottom of the thin film electrode layer. The micro LED is integrated in the flexible nerve probe through contact type laser transfer printing to serve as a light stimulation light source, the preparation success rate is remarkably increased, heat radiated outwards during light stimulation is reduced, and damage to brain tissue of the brain caused by high-Young-modulus optical fibers is avoided; meanwhile, a rigid-flexible variable shape memory layer is also integrated, so that the Young modulus of the probe is high when the in-vitro temperature is relatively low, fixed-point implantation can be directly carried out without an auxiliary tool, the Young modulus of the probe is reduced along with the rise of the body temperature after the probe is implanted into the body, and the probe finally adapts to the mechanical tissue strength of the brain; therefore, the implantation efficiency and the mechanical adaptability of the probe to brain tissues are improved, and micron-scale accurate implantation of the probe, neuron-scale positioning of electrical stimulation and light stimulation points and long-term stable recording of electrophysiological signals are realized.

The invention belongs to the technical field of nutritional compositions, and particularly relates to a composition, a preparation method thereof and application of the composition in protecting brain health. The composition provided by the invention is prepared from docosahexaenoic acid, 3-sialic acid lactose and phosphatidylserine. The composition is clear in sleep improvement effect, can effectively solve the problem of sleep maintenance caused by sleep deprivation, has the effects of protecting neural functions, improving memory and relieving anxiety from multiple dimensions, and can repair brain tissue damage and protect brain health. Based on the composition, products for assisting in improving memory, preventing and treating insomnia and anxiety, regulating neurodevelopmental disorders, protecting brain health and improving concentration can be developed, the health requirements of different people are comprehensively met, and the application value is high.

This invention belongs to the field of pharmaceutical technology, specifically relating to a quinazoline-azaindole compound, its preparation method, and its application in treating Alzheimer's disease. The quinazoline-azaindole compound of this invention regulates NF-κB by inhibiting DYRK1A. k B. A series of signaling pathways, including PI3k-Akt, achieve anti-neuroinflammatory effects; quinazoline-azaindole compounds can reduce the expression of inflammatory factor-related genes in an LPS-induced BV2 microglial inflammation model, thereby reducing the levels of inflammatory factors in the hippocampus and cortex, alleviating neuronal pathological damage caused by neuroinflammation, and improving cognitive impairment caused by neuroinflammation; in summary, quinazoline compounds inhibit DYRK1A and downregulate NF-κB signaling pathways. k It can reduce the expression and release of inflammatory factors, improve brain tissue pathology, and alleviate cognitive impairment through signaling pathways such as B, and has significant clinical application value.

The present application belongs to the field of functional substance research, and particularly relates to a nutritional composition for promoting brain development and use thereof. The nutritional composition provided by the present application comprises essential active ingredients shown in (i) and (ii) as follows: (i) lysophosphatidylethanolamine; (ii) 3'-SL; wherein the essential active ingredient shown in (i) at least comprises lysophosphatidylethanolamine with a fatty acid chain with a length of 14-22 carbon atoms connected at the sn-1 position, and in the nutritional composition, the mass ratio of the essential active ingredient shown in (i) to the essential active ingredient shown in (ii) is 1:(1-450). The combination of lysophosphatidylethanolamine and breast milk oligosaccharide 3'-SL can effectively promote the overall development of the body, especially the brain development, and improve the relative gene expression amount of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, thereby effectively assisting the improvement of cognitive ability.

The invention belongs to the technical field of molecular biology, and relates to an application of transferrin (TF) as an internal reference protein in preparation of a reagent for detecting exosome proteins of neurodegenerative diseases. The TF can maintain a stable expression level in nerve cells, brain tissues, blood plasma and serum-derived exosomes of a subject suffering from neurodegenerative diseases, including Alzheimer's disease, mild cognitive impairment, amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease, and also including neurodegenerative diseases such as Alzheimer's disease, mild cognitive impairment, amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease. The TF expression variation coefficient is obviously lower than that of a common exosome marker, and the expression level of TF has stronger correlation with the total protein amount of the exosome and is not influenced by external factors such as cell inflammation stress. The TF as the internal reference protein has more excellent performance, can help to more accurately reflect the total loading amount of the sample, and provides a more stable and reliable standardized tool for the field of exosome research.

A system may comprise hardware and software configured to perform computing functions that mimic at least one computing function of a human brain, wherein the hardware and software comprises: analog circuitry configured to perform signal processing of neural signals obtained from living brain tissue using at least one sensor, a computer system comprising a processor, memory accessible by the processor, and computer program instructions stored in the memory and executable by the processor digital circuitry and software configured to process the obtained neural signals to generate a representation of a brain function from the obtained neural signals, and to generate parameters for use by analog and digital circuitry to perform computing functions that mimic at least one computing function of a human brain, and the analog and digital circuitry configured to use the generated parameters to perform computing functions that mimic at least one computing function of a human brain.

The invention relates to the technical field of traditional Chinese medicines, relates to new application of a traditional Chinese medicine composition, and in particular relates to application of the traditional Chinese medicine composition in preparation of a medicine for preventing and / or treating migraine. The traditional Chinese medicine composition is prepared from cassia twig, white peony root, honey-fried licorice root, ginger, jujube, ginseng, Chinese angelica, salted morinda officinalis and dwarf lilyturf tuber. The traditional Chinese medicine composition provided by the invention can obviously reduce serum NO and trigeminal nervous tissue SP content of migraine rats, increase trigeminal nervous tissue DA content, obviously improve head and face pain threshold and brain tissue DA content of the migraine rats and reduce brain tissue PGE2 content, and has a good treatment effect on migraine.

This application relates to the field of medicinal chemistry, specifically disclosing a piperidine derivative, a pharmaceutical composition, its uses, and a method for preparation. The piperidine derivative has the structure of general formula (I). This piperidine derivative can significantly improve the learning and memory abilities of Aβ-induced Alzheimer's disease model rats and effectively reduce acetylcholinesterase activity in brain tissue, providing a potential candidate for the development of novel Alzheimer's disease treatments.

The invention belongs to the technical field of biology, and particularly relates to a construction method of a respiratory syncytial virus infected mouse model. Disodium clodronate liposome with the concentration of 4ng / mL is injected into the lateral ventricle of the mouse through stereotactic positioning of the brain. 48h after injection, mouse brain tissues are taken to detect the activation state of microglial cells through immunofluorescence and WB, after it is confirmed that the microglial cells are inhibited, RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments are carried out on the mouse, and after the 5th day after virus infection, the mouse is infected by the RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments. Likewise, mouse brain tissue is taken for virus load detection, and neuropathological changes of the mouse brain tissue are observed through HE staining, immunofluorescence and TUNEL staining, so that the method can be used for constructing a research model of RSV-related nervous system diseases.

The invention discloses application of a reagent for detecting an SLC17A7 autoantibody in diagnosis of nervous system diseases. By comparing different fluorescence modes of autoimmune antibodies related to IgG of healthy people in mouse brain tissue slices of patients with nervous system diseases, it is found that fluorescence signals only exist in the patients with nervous system diseases and do not exist in the healthy people, and it is prompted that the patients possibly have the autoimmune antibodies. According to the invention, IgG specific protein related to nervous system diseases is sought through a co-immunoprecipitation technology, a specific SLC17A7 autoantibody is found through cell immunofluorescence (CBA) detection, verification is carried out in cerebrospinal fluid, and finally it is determined that the SLC17A7 autoantibody can be used as a specific marker for diagnosis of nervous system autoimmune diseases. The SLC17A7 is taken as a detection antigen, detection of the expression of the SLC17A7 autoantibody can be applied to a kit for detecting the SLC17A7 autoantibody, the kit can be applied to detection of nervous system diseases, markers for identifying the nervous system diseases are enriched, and the detection accuracy of nervous system related diseases is improved.

The application provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine preparation is composed of nacre, antelope horn powder, dragon's blood, Herba Schizonepetae, Prunella vulgaris, Stink-bug, Smilax riparia, bamboo juice, dried tangerine or orange peel, clubmoss, radix puerariae, Zizania aquatica and leaf of Chinese pear. The preparation has a significant therapeutic effect on cerebral hemorrhage, can obviously improve the neurological deficit of cerebral hemorrhage rats, reduce the water content of brain tissue to alleviate brain edema, simultaneously alleviate the inflammatory response in the body, thereby playing a neuroprotective effect on cerebral hemorrhage rats. In addition, the preparation can obviously improve the consciousness state of cerebral hemorrhage patients, alleviate the degree of neurological deficit, relieve the related TCM syndromes of the patients, simultaneously effectively improve the daily life ability of the patients, significantly improve the total effective rate of clinical treatment, and no obvious adverse reactions are observed in the treatment process, and the safety is good, thereby providing a safe and effective treatment scheme for the conservative treatment of cerebral hemorrhage.

The application belongs to the technical field of medicine, and particularly relates to a muscone derivative, a preparation method and application thereof. The muscone derivative cyclopentadecanedione monoxime has obvious advantages over muscone and other derivatives in improving the MCAO rat mNSS score, microcirculation blood flow, reducing the cerebral infarction rate, the cortical and hippocampal neuron necrosis rate, and the brain water content, and increasing the SOD and CAT contents of the rat brain tissue which are abnormally reduced due to ischemia, and is a potential effective drug for cerebral ischemia-reperfusion injury.

The invention provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of nacre mother of pearl, antelope horn powder, dragon's blood, motherwort fruit, selfheal, aspongopus, radix actinidiae chinensis, bamboo juice, pericarpium citri reticulatae, selaginella tamariscina, radix puerariae, zizania aquatica and folium eriobotryae. The traditional Chinese medicine composition can obviously improve neurological impairment of cerebral hemorrhage rats, reduce the water content of brain tissues to relieve encephaledema and reduce inflammatory response in vivo, thereby playing a role in protecting the nerves of the cerebral hemorrhage rats. Besides, the preparation can obviously improve the consciousness state of a cerebral hemorrhage patient, relieve the degree of neurological impairment, relieve related traditional Chinese medicine syndromes of the patient, effectively improve the daily living ability of the patient and obviously improve the total effective rate of clinical treatment, no obvious adverse reaction is observed in the treatment process, and the preparation is good in safety and free of toxic and side effects. And a safe and effective treatment scheme is provided for the conservative treatment of cerebral hemorrhage.

The present application belongs to the technical field of nutrient research, and particularly relates to a nutrient composition for promoting brain development and use thereof. The nutrient composition provided by the present application comprises two necessary components: i) lysophosphatidyl ethanolamine; and ii) docosahexaenoic acid; and the mass ratio of the lysophosphatidyl ethanolamine to the docosahexaenoic acid in the nutrient composition is 1:(10-2100). The combination of lysophosphatidyl ethanolamine and docosahexaenoic acid can effectively promote the overall growth and development of the body, especially the brain development, increase the expression levels of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, and effectively assist the improvement of cognitive ability.

The invention relates to the technical field of biological medicine and polymer targeted delivery, and provides an oligodendrocyte-derived exosome and application thereof in preparation of a medicine for treating traumatic brain injury. Comprising the following steps: separating and culturing primary oligodendroglia cells from brain tissues; placing the maturely cultured oligodendroglia cells in a sugar-free and serum-free culture medium, performing oxygen-glucose deprivation treatment in an anoxic environment, then continuously culturing in a normal sugar-containing culture medium under a normal oxygen condition, and collecting cell culture supernate; and separating the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment from the supernate by adopting a gradient ultracentrifugation method to obtain the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment. The exosome derived from the oligodendroglia is applied to preparation of the medicine for treating the traumatic brain injury and has the advantages of being high in targeting performance and good in penetrability, that is, the exosome is used as a natural carrier, the defect that a traditional traumatic brain injury medicine is difficult to penetrate through a blood brain barrier is perfectly overcome, and the exosome can efficiently enter brain tissue and be taken by microglia.

Among the various aspects of the present disclosure is the provision of a noninvasive and localized brain liquid biopsy using focused ultrasound. Briefly, therefore, the present disclosure is directed to methods and systems to identify brain lesion or tumor characteristics without the need for a solid brain biopsy.

The application discloses application of RVG-Exo-miR-3059-5 in treating cerebral stroke. The RVG-Exo-miR-3059-5 is prepared by using gene engineering technology to perform brain targeting modification on EPCs-Exo and load miR-3059-5p drugs. The experiment proves that the RVG-Exo-miR-3059-5 can effectively target brain tissues, can prevent or treat cerebral stroke, and can improve the prognosis of cerebral stroke patients.

The invention provides a gene composition for screening or diagnosing Parkinson's syndrome and application of the gene composition, and belongs to the technical field of biology. The invention provides a set of seven genes in brain tissue, a set of eight genes in cerebrospinal fluid, a set of ten genes in blood and a set of eight DNA methylation sites in blood, and at least one of the sets can be used as a marker for screening or diagnosing Parkinson's syndrome. Meanwhile, based on the genotype, expression level or methylation level data of the marker, a model for diagnosing the Parkinson's syndrome is constructed by combining a maximum logic intelligent classifier, and the subtype of the Parkinson's syndrome is determined. The method does not depend on a p value and multiple inspection correction, but establishes the model by searching the minimum and optimal gene combinations capable of perfectly distinguishing cases and contrasts, thereby fundamentally avoiding the problems of overfitting and insufficient statistical efficacy.

The present invention relates to use of PAK4 and CRTC1 or the treatment or diagnosis of a degenerative brain disease. Specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of a degenerative brain disease comprising PAK4 (p21-activated kinase 4) or a PAK4 activator as an effective ingredient. In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of a degenerative brain disease comprising a CRTC1 expression enhancer or activator as an effective ingredient, a diagnostic kit for a degenerative brain disease comprising an agent for detecting CRTC1, and a method for screening a substance for the prevention or treatment of a degenerative brain disease, comprising (a) applying a candidate drug to brain tissue or brain cells containing CRTC1 gene or CRTC1 protein; (b) measuring the degree of phosphorylation in CRTC1; and (c) determining the candidate drug as a substance for the prevention or treatment of a degenerative brain disease when the measurement in step (b) indicates that the phosphorylation in CRTC1 is increased.

The application discloses a compound for treating diseases related to ischemic brain injury, and the compound has the structure shown in the following formula (II). The compound has higher bioavailability, higher distribution concentration in rat plasma and brain tissue, and good effect on ischemic brain injury.

The invention belongs to the technical field of biological peptide enzymolysis, and particularly discloses a sheep three-medullary peptide composition for assisting in improving memory and application of the sheep three-medullary peptide composition. The sheep three-medullary peptide composition is prepared from the following components in parts by mass: 40 to 50 parts of sheep three-medullary peptide, 20 to 35 parts of sheep colostrum peptide and 10 to 25 parts of casein hydrolyzed peptide. The invention discloses a sheep three-medullary peptide composition for assisting in improving memory and application thereof, which can obviously improve the level of acetylcholine in the brain and inhibit the activity of acetylcholin esterase to enhance nerve conduction, and can effectively relieve the damage of oxidative stress to brain tissues by improving the activity of SOD and GSH-Px and reducing the content of MDA.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a drug-loaded microsphere as well as a preparation method and application thereof. According to the invention, the bioadhesive material is used as a carrier and is mixed with the drug to form the drug-loaded microspheres with nasal mucosa adhesiveness, so that the residence time of the drug in the nasal cavity is prolonged, meanwhile, the stimulation of the drug to the nasal mucosa is reduced, the bioavailability and intracerebral distribution are improved, the administration dosage is reduced, the sustained release effect of the drug is realized, and adverse reactions of gastrointestinal tracts and the like are avoided. The drug-loaded microsphere provided by the invention has the following characteristics: because the nasal mucosa area is large, submucosa blood vessels are very rich, and the drug can be rapidly absorbed and enter systemic circulation from the blood vessels; the first-pass effect during oral administration of the medicine is avoided, and the bioavailability is relatively high; a unique direct channel exists between the nasal cavity and the brain in anatomy, and various macromolecular polypeptides and small molecular drugs can bypass a blood-brain barrier to enter cerebrospinal fluid or brain tissue after being absorbed by the nose.

The invention provides a method for evaluating toxicity of pollutants to a nervous system based on intestinal-brain axis signals. The method comprises the following steps: collecting brain tissues and intestinal tissues of animals exposed to the pollutants; respectively screening target spots which have a key interference effect on metabolism of the 5-hydroxytryptamine and characteristic microorganisms in intestinal tracts under a pollutant exposure condition; further screening to obtain a core microorganism with high interference correlation with a 5-hydroxytryptamine metabolic pathway; the neurotoxicity of the pollutants is evaluated on the basis of intestinal-brain axis signals by taking the screened target spot which has a key interference effect on the metabolism of the 5-hydroxytryptamine under the exposure condition of the pollutants and the core microorganism which has high interference correlation with the metabolism of the 5-hydroxytryptamine as markers. A comprehensive analysis system which takes intestinal-brain axis signals as a core pathway and covers a micro-ecology-metabolism-neural network is constructed by combining structural changes of intestinal microflora and disturbance of a 5-hydroxytryptamine metabolic pathway, and the toxicity of pollutants to a nervous system can be systematically evaluated.

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

The invention discloses a Zika virus ZIKV (Zika virus, ZIKV) challenging animal model construction method, which comprises the following steps: inoculating ZIKV to an F344 rat through an intracranial injection way for modeling to obtain the ZIKV challenging animal model. After inoculation of ZIKV, obvious ZIKV load can be detected in brain tissues, spleens and reproductive organs of F344 rats, and the load of ZIKV is increased along with prolonging of time. It is shown that the ZIKV challenge model is successfully constructed, and the ZIKV challenge model can be applied to related researches of ZIKV infection mechanisms, vaccine research and development, anti-ZIKV drug research and development and the like.

The invention provides a traditional Chinese medicine composition for resisting Alzheimer's disease as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following active ingredients in parts by weight: 6-50 parts of astragalus membranaceus, 6-50 parts of salvia miltiorrhiza, 6-50 parts of uncaria, 3-30 parts of ginkgo leaves, 3-30 parts of gardenia, 3-30 parts of cistanche, 3-30 parts of rhodiola rosea, 3-30 parts of corydalis tuber, 3-30 parts of ligusticum wallichii, 3-30 parts of rhizoma anemarrhenae, 3-30 parts of medlar, 3-30 parts of semen raphani, 3-30 parts of teasel root, 3-30 parts of golden cypress, 3-30 parts of acorus tatarinowii, 3-30 parts of pseudo-ginseng and 2-30 parts of coptis chinensis. The raw materials of the medicine are common, the preparation method is simple and easy to operate, the medicine has wide application value, after oral administration, cognitive impairment of a rat model with the Alzheimer disease can be remarkably improved, the content of inflammatory factors IL-6 and IL-1beta in brain tissue is reduced, meanwhile, the number of activated microglial cells and astrocytes in the brain tissue is reduced, and the curative effect of the medicine is improved. The compound can inhibit excessive phosphorylation of tau protein in brain tissues, and has a new application of an anti-Alzheimer disease drug.

The invention discloses application of a compound high spot-nourishing tablet in preparation of a medicine for treating cerebral ischemia-reperfusion injury. A rat cerebral ischemia reperfusion injury model is established through middle cerebral artery embolism, and serum, pathology and infarction areas of rats are observed and detected. Results show that the neurological score of the model group ZeaLonga is significantly increased, pathological changes are large, proinflammatory factors TNF-alpha, IL-6 and IL-1beta are significantly increased, oxidation promoting MDA is significantly increased, and antioxidant SOD expression is significantly increased. And compared with a model group, the weight, the neurological score and the survival rate are obviously improved. The results of HE staining, TTC staining and TUNEL staining show that the nerve cell morphology, arrangement, infarct area and cell apoptosis condition of each administration group are obviously improved. The application provided by the invention can improve the behavior of rats, reduce the infarct area, protect nerve cells and reduce the apoptosis of ischemic regions; by reducing inflammation and oxidation in rat brain tissues, damage of inflammation and oxidative stress to the rat brain tissues is reduced.

The invention discloses application of CKB K11 lactic acid modification as a cerebral apoplexy I / R injury diagnosis or neuroprotection drug target, and belongs to the technical field of biological medicine. The CKB K11 lactic acid modification provided by the invention can obviously improve the cerebral apoplexy ischemia reperfusion injury and motor function, and the CKB K11 lactic acid modification is closely related to the cerebral apoplexy ischemia reperfusion injury and can be used as a specific diagnosis index of the cerebral apoplexy ischemia reperfusion injury. By detecting the CKB K11 lactic acid modification level in a biological sample, the brain tissue damage degree and the postoperative recovery condition of a detected object can be rapidly and accurately evaluated, and a new effective means is provided for clinical diagnosis.